Search
Evotec SE
EVOAdd to Watchlist
2.900USD
+0.050+1.75%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.03BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.75%
5 Days
+7.81%
1 Month
-5.54%
6 Months
-5.84%
Year to Date
-5.84%
1 Year
-31.28%
Key Figures
2.920Open
2.930High
26.22KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.01%Turnover Ratio
2.850Prev. Close
2.870Low
43.59KTurnover
LossP/E Static
1.27P/B
0.00%Div Yield TTM
-11.32%ROA
4.44052wk High
1.27Volume Ratio
-212.07MNet Profit
355.33MShares
-0.6369EPS TTM
1.93Beta
-25.21%ROE
2.30852wk Low
2.11%Amplitude
-1.00%Gross Margin
1.03BMarket Cap
-0.83Reward/Risk
1.66%Risk Rate
TradingKey Stock Score of Evotec SE
Currency: USD Updated: 2026-07-01Key Insights
Evotec SE's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 147 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 4.67.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Evotec SE's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Evotec SE Highlights
StrengthsRisks
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 888.92M.
Overvalued
The company’s latest PE is -4.47, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 9.58M shares, decreasing 5.75% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 142.99K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.70.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
4.667
Target Price
+66.67%
Upside Space
Evotec SE News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Evotec SE Info
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Ticker SymbolEVO
CompanyEvotec SE
CEOWojczewski (Christian)
Websitehttps://www.evotec.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52842.500
+588.200 (+1.13%)
29311.400
-487.900 (-1.64%)
7471.500
-4.000 (-0.05%)
14803.000
-552.000 (-3.60%)
68148.000
-1337.000 (-1.92%)
6352.800
+77.400 (+1.23%)
68.344
+0.376 (+0.55%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4121.910
+91.140 (+2.26%)
FAQs
What is the current price of Evotec SE (EVO)?
The current price of Evotec SE (EVO) is 2.85.
What is the symbol of Evotec SE?
The ticker symbol of Evotec SE is EVO.
What is the 52-week high of Evotec SE?
The 52-week high of Evotec SE is 4.44.
What is the 52-week low of Evotec SE?
The 52-week low of Evotec SE is 2.31.
What is the market capitalization of Evotec SE?
The market capitalization of Evotec SE is 1.03B.
Is Evotec SE (EVO) currently rated as Buy, Hold, or Sell?
According to analysts, Evotec SE (EVO) has an overall rating of signal_hold, with a price target of 4.67.
What is the Earnings Per Share (EPS TTM) of Evotec SE (EVO)?
The Earnings Per Share (EPS TTM) of Evotec SE (EVO) is -0.33.